Skip to content

A randomized controlled trial comparing sequential of two shots of CFA vs CFA + rFSH for Elective Fertility Preservation. The 2-shot protocol.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-506162-31-00
Acronym
FSD-SEQ-2023-09
Enrollment
194
Registered
2023-10-26
Start date
2023-12-12
Completion date
2025-09-09
Last updated
2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

To compare the number of MII oocytes retrieved after final oocyte maturation with a 2-shot sequential administration of CFA or a unique administration of CFA followed by daily rFSH for controlled ovarian stimulation in patients undergoing elective fertility preservation.

Detailed description

Total number of oocytes retrieved, Endocrine profile on the day of trigger (FSH, LH, estradiol, progesterone), Incidence of OHSS, Quality of life questionnaire “FertiQoL”, Length of stimulation

Interventions

DRUGElonva 100 micrograms solution for injection
DRUGCerazet 75 microgramos comprimidos recubiertos con película

Sponsors

Santiago Dexeus Font Fundacio Privada
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
To compare the number of MII oocytes retrieved after final oocyte maturation with a 2-shot sequential administration of CFA or a unique administration of CFA followed by daily rFSH for controlled ovarian stimulation in patients undergoing elective fertility preservation.

Secondary

MeasureTime frame
Total number of oocytes retrieved, Endocrine profile on the day of trigger (FSH, LH, estradiol, progesterone), Incidence of OHSS, Quality of life questionnaire “FertiQoL”, Length of stimulation

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026